AstraZeneca AZN announced that the FDA has accepted the supplemental new drug application (sNDA), seeking approval for the ...

On Thursday, the FDA accepted and granted Priority Review to AstraZeneca Plc’s (NASDAQ:AZN) supplemental marketing ...

AstraZeneca's supplemental New Drug Application for Calquence (acalabrutinib) has been granted Priority Review by the US FDA ...

AstraZeneca’s supplemental New Drug Application (sNDA) for CALQUENCE® (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with previously ...

Acalabrutinib, a Bruton tyrosine kinase inhibitor, is currently approved under the brand name Calquence ® for MCL in patients who have received at least 1 prior therapy. It is also indicated for the ...

Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it ...

Instead of four equal quarterly distributions, AstraZeneca insists on two payments per year, with a greater portion announced ...

AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL). Calquence (acalabrutinib ...

(Alliance News) - AstraZeneca PLC on Thursday said its cancer treatment Calquence obtained priority review by the US Food & Drug Administration for a form of lymphoma.

Billionaire investor George Soros became nearly a household name in the early 1990’s by shorting the British pound and making ...

AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuster ...

AstraZeneca AZN stock has risen 13.6% in the past six months, outperforming an increase of 7.1% for the industry. AstraZeneca ...